Recommended Products
Application
N-Acetylheparin, derivitized porcine mucosal heparin without anticoagulant properties, may be used to protect cardiac, vascular and neural tissues by inhibiting complement activation and neutrophil infiltration of the damage site.
Preparation Note
Prepared from porcine mucosal heparin by a modification of the method of Nagasawa, K. and Inoue, Y., Methods Carb. Chem., 8, 291 (1980).
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Y Hua et al.
Journal of neurosurgery, 92(6), 1016-1022 (2000-06-06)
Brain edema formation following intracerebral hemorrhage (ICH) appears to be partly related to erythrocyte lysis and hemoglobin release. Erythrocyte lysis may be mediated by the complement cascade, which then triggers parenchymal injury. In this study the authors examine whether the
P C Kouretas et al.
Journal of molecular and cellular cardiology, 30(12), 2669-2682 (1999-02-17)
Heparin, which is widely used clinically, has recently been shown to have specific properties affecting the vascular endothelium. We hypothesized that heparin stimulates endothelial nitric oxide synthase (eNOS) activity by a mechanism independent of its anticoagulant properties and dependent on
P C Kouretas et al.
Circulation, 99(8), 1062-1068 (1999-03-02)
Coronary endothelial dysfunction after brief ischemia-reperfusion (IR) remains a clinical problem. We investigated the role of heparin and N-acetylheparin, a nonanticoagulant heparin derivative, in modulating coronary endothelial function after IR injury, with an emphasis on defining the role of the
J L Park et al.
Pharmacology, 58(3), 120-131 (1999-02-02)
The ability of the heparin derivative, N-acetylheparin (NHEP) to protect the heart from regional ischemia/reperfusion injury was examined in vivo. NHEP (2 mg/kg i.v.) or vehicle was administered 2 h before occlusion of the left circumflex coronary (LCX) artery. Open-chest
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service